Drugs / NKT3964
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06586957 | Sep 2024 → Jan 2029 expected | endometrial carcinoma, gastric carcinoma, metastatic neoplasm, ovarian carcinoma +3 | NiKang Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NKT3964 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06586957 ↗ |
| Route | Oral | “oral dosing NKT3964” NCT06586957 ↗ |
| Target | CDK2 | “Oral CDK2 Degrader” NCT06586957 ↗ |